Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism

Area of Science:

• Endocrinology
• Surgical Oncology
• Cardiovascular Medicine

Background:

• Primary aldosteronism management involves biochemical cure and clinical benefits like reduced blood pressure (BP) and antihypertensive medication use.
• Achieving these clinical benefits can decrease risks of cardiovascular and cerebrovascular events.

Purpose of the Study:

• To evaluate changes in BP and antihypertensive medication use after surgery for primary aldosteronism.
• To assess clinical outcomes in an international patient cohort undergoing adrenalectomy.

Main Methods:

• A cohort study included 435 patients who underwent unilateral adrenalectomy for primary aldosteronism across 16 international centers.
• Clinical success was defined by postoperative BP and medication use, with outcomes assessed around 6 months post-surgery.

Main Results:

• 27.1% of patients were cured (normotensive, no medications), 31.0% showed clear improvement, and 41.8% had no clear success (persistent hypertension).
• In the 'no clear success' group, BP significantly decreased (systolic by 9 mmHg, diastolic by 3 mmHg), and medication use dropped from 3 to 2 agents.
• Over 41% in the 'no clear success' group experienced a systolic BP decrease of at least 10 mmHg.

Conclusions:

• Adrenalectomy often leads to a normotensive state and reduced medication needs in primary aldosteronism patients.
• Even patients with persistent postoperative hypertension can experience significant BP reduction and decreased antihypertensive drug use, indicating clinical benefit.